The Manchester guidelines for contralateral risk-reducing mastectomy

about

Attitudes to contralateral risk reducing mastectomy among breast and plastic surgeons in England.Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer.

P2860

Q37556568-EFE204AF-6187-4E8A-96C5-F621AE314B13 Q38658383-70DA1599-B92C-4F49-9B5E-92AF45C142B6

P2860

The Manchester guidelines for contralateral risk-reducing mastectomy

Item

http://www.wikidata.org/entity/Q35923270

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

The Manchester guidelines for contralateral risk-reducing mastectomy

@ast

The Manchester guidelines for contralateral risk-reducing mastectomy

@en

type

Item

label

The Manchester guidelines for contralateral risk-reducing mastectomy

@ast

The Manchester guidelines for contralateral risk-reducing mastectomy

@en

prefLabel

The Manchester guidelines for contralateral risk-reducing mastectomy

@ast

The Manchester guidelines for contralateral risk-reducing mastectomy

@en

P1476

The Manchester guidelines for contralateral risk-reducing mastectomy

@en

P2093

G L Ross

http://www.w3.org/2001/XMLSchema#string

L Barr

http://www.w3.org/2001/XMLSchema#string

Narendra Nath Basu

http://www.w3.org/2001/XMLSchema#string

P2860

Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment

Prophylactic mastectomy for the prevention of breast cancer

Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study.

Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status

Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.

Risk-reduction mastectomy: clinical issues and research needs.

Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

Declining incidence of contralateral breast cancer in the United States from 1975 to 2006

The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services.

Contralateral risk-reducing mastectomy: review of risk factors and risk-reducing strategies.

P2888

s12957-015-0638-y

P304

237

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12957-015-0638-Y

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gareth Evans

P577

2015-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280911207

http://www.w3.org/2001/XMLSchema#string

P6179

1016530707

http://www.w3.org/2001/XMLSchema#string

P698

26245209

http://www.w3.org/2001/XMLSchema#string

P932

4527227

http://www.w3.org/2001/XMLSchema#string

The Manchester guidelines for contralateral risk-reducing mastectomy

about

P2860

P2860

The Manchester guidelines for contralateral risk-reducing mastectomy

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P5875

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P5875

P6179

P698

P932